Skybiotech Life Sciences Profile
Key Indicators
- Authorised Capital ₹ 10.50 Cr
as on 23-10-2024
- Paid Up Capital ₹ 9.49 Cr
as on 23-10-2024
- Company Age 10 Year, 4 Months
- Last Filing with ROC 31 Mar 2023
- Satisfied Charges ₹ 1.00 Cr
as on 23-10-2024
- Revenue 19.08%
(FY 2023)
- Profit 253.32%
(FY 2023)
- Ebitda 10.68%
(FY 2023)
- Net Worth 4.54%
(FY 2023)
- Total Assets 4.51%
(FY 2023)
About Skybiotech Life Sciences
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 10.50 Cr and a paid-up capital of Rs 9.49 Cr.
The company has closed loans amounting to ₹1.00 Cr, and has no open charges as per Ministry of Corporate Affairs (MCA) records.
Poonam Rathi and Prakashchandra Rathi serve as directors at the Company.
- CIN/LLPIN
U24100MH2014PTC256924
- Company No.
256924
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
06 Aug 2014
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Aurangabad, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media-
What products or services does Skybiotech Life Sciences Private Limited offer?
Skybiotech Life Sciences Private Limited offers a wide range of products and services, including Antipyretic Medication, Paracetamol Tablets, Pharmaceutical Syrup, Oral Suspension, Antibacterial Drugs, Antibiotic Medicine, Metformin Tablets, Glimepiride Metformin Tablet, Anti Infective Drugs & Medicines, Malaria Medicine.
Who are the key members and board of directors at Skybiotech Life Sciences?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Poonam Rathi  | Director | 22-May-2024 | Current |
| Prakashchandra Rathi | Director | 22-May-2024 | Current |
Financial Performance of Skybiotech Life Sciences.
Skybiotech Life Sciences Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 19.08% increase. The company also saw a substantial improvement in profitability, with a 253.32% increase in profit. The company's net worth moved up by a moderate rise of 4.54%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Skybiotech Life Sciences?
In 2023, Skybiotech Life Sciences had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Springfield Exim Private LimitedActive 16 years 2 monthsPoonam Rathi and Prakashchandra Rathi are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Bank Of Maharashtra Creation Date: 06 Aug 2015 | ₹1.00 Cr | Satisfied |
How Many Employees Work at Skybiotech Life Sciences?
Skybiotech Life Sciences has a workforce of 63 employees as of Apr 04, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Skybiotech Life Sciences, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Skybiotech Life Sciences's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
